BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27

• Press Releases

  TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

  July 22, 2026

   · 

  8 min read
• Press Releases

  RE:YOU Launches Hair Revival Serum and Announces Positive Early Clinical Results from An Ongoing 190-Participant Study

  July 22, 2026

   · 

  1 min read
• Press Releases

  D&D Pharmatech Announces The Lancet Gastroenterology & Hepatology Publication of Phase 2 Data Demonstrating Rapid, Weight-Independent Activity of Zabopegdutide (DD01) in MASLD/MASH

  July 22, 2026

   · 

  6 min read
• Press Releases

  Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance

  July 22, 2026

   · 

  5 min read
• 

  Job Trends

  6 companies hiring in Cambridge now

  Looking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.

  July 22, 2026

   · 

  1 min read

   · 

  Angela Gabriel
• Press Releases

  BIO Asia-Taiwan 2026 Unites 60 Countries, Showcasing Taiwan as a Global Biotech Innovation Partner

  July 22, 2026

   · 

  4 min read
• Press Releases

  Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

  July 22, 2026

   · 

  5 min read
• Press Releases

  Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline

  July 22, 2026

   · 

  7 min read
• Press Releases

  Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026

  July 22, 2026

   · 

  3 min read
• Press Releases

  Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma

  July 22, 2026

   · 

  5 min read